日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Synergistic anti-tumor activity of ciclopirox olamine and metformin in triple-negative breast cancer

环吡咯烷酮和二甲双胍在三阴性乳腺癌中的协同抗肿瘤活性

Wu, Yakun; Lyu, Hui; Tan, Congcong; Larsen, Margaret E; Tang, Shou-Ching; Huang, Shile; Liu, Bolin

HER3 promotes triple-negative breast cancer progression by upregulating PHF8 via miR-34b-5p-dependent mechanism.

HER3 通过 miR-34b-5p 依赖性机制上调 PHF8,从而促进三阴性乳腺癌的进展。

Lyu Hui, Tan CongCong, Wu Yakun, Larsen Margaret E, Yu Qingzhao, Kang Guobin, Wood Charles, Tang Shou-Ching, Liu Bolin

First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors

首次人体 I 期开放标签研究,评估抗 TIM-3 单克隆抗体 INCAGN02390 对特定晚期或转移性实体瘤患者的疗效

Gutierrez, Martin E; Tang, Shou-Ching; Powderly, John D 2nd; Balmanoukian, Ani S; Hoyle, Paul E; Dong, Zhiwan; Cheng, Lulu; Gong, Xiaohua; Janik, John E; Bourayou, Nawel; Hamid, Omid

Beyond checkpoint inhibitors: the three generations of immunotherapy

超越免疫检查点抑制剂:免疫疗法的三代发展

Schaub, John; Tang, Shou-Ching

EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)

EA1211:FDG-PET/CT 中期研究预测 HER2 阳性乳腺癌对新辅助治疗的反应(DIRECT 试验)

Hennessy, Maeve A; Gatsonis, Constantine; Jacene, Heather; Connolly, Roisin M; Burnette, Brian L; Stringer-Reasor, Erica M; Romanoff, Justin; Taurone, Alexander; O'Sullivan, Ciara C; Le-Petross, Huong T; Stearns, Vered; Fowler, Amy M; Tang, Shou-Ching; Sepulveda, Karla A; DeMichele, Angela M; Mankoff, David A; Wolff, Antonio C

Influence of antibody-drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis

抗体药物偶联物裂解性、药物抗体比和游离有效载荷浓度对全身毒性的影响:系统评价和荟萃分析

Tang, Shou-Ching; Wynn, Carrie; Le, Tran; McCandless, Martin; Zhang, Yunxi; Patel, Ritesh; Maihle, Nita; Hillegass, William

Correction: M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way

更正:M6A相关的TSUC7抑制通过Notch信号通路激活依赖的方式导致肺腺癌对厄洛替尼产生耐药性。

Li, Kai; Peng, Zi-Yang; Gao, Shan; Wang, Qing-Shi; Wang, Rui; Li, Xiang; Xiao, Guo-Dong; Zhang, Jing; Ren, Hong; Tang, Shou-Ching; Sun, Xin

Author Correction: The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas

作者更正:免疫疗法候选药物TNFSF4可能有助于在乳腺癌中诱导有前景的免疫反应。

Li, Kai; Ma, Lei; Sun, Ye; Li, Xiang; Ren, Hong; Tang, Shou-Ching; Sun, Xin

Correction: MiR-129 blocks estrogen induction of NOTCH signaling activity in breast cancer stem-like cells

更正:miR-129阻断雌激素诱导乳腺癌干细胞样细胞中NOTCH信号通路活性

Xiao, Guodong; Li, Xiang; Li, Gang; Zhang, Boxiang; Xu, Chongwen; Qin, Sida; Du, Ning; Wang, Jichang; Tang, Shou-Ching; Zhang, Jing; Ren, Hong; Chen, Ke; Sun, Xin

The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options

口服选择性雌激素受体阻滞剂(SERD)和其他新型雌激素受体抑制剂的研发竞赛:近期临床试验结果及其对治疗选择的影响

Wang, Yating; Tang, Shou-Ching